Concerns about cardiotoxicity in the HERA trial – Authors' reply - ScienceDirect

The Lancet

Volume 390, Issue 10114, 23 December 2017–5 January 2018, Pages 2767-2768

The Lancet

https://doi.org/10.1016/S0140-6736(17)31940-2 Get rights and content

References (2)

DA Cameron et al.
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
Lancet
(2017)
TM Suter et al.
Trastuzumab-associated cardiac adverse effects in the Herceptin Adjuvant trial
J Clin Oncol
(2007)

Cited by (0)

© 2017 Elsevier Ltd. All rights reserved.